Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

被引：0
|
作者：
Bei Wang
Rong Deng
Stefanie Hennig
Tanja Badovinac Crnjevic
Monika Kaewphluk
Matts Kågedal
Angelica L. Quartino
Sandhya Girish
Chunze Li
Whitney P. Kirschbrown
机构：
[1] Genentech,
[2] Inc.,undefined
[3] Certara,undefined
[4] Inc.,undefined
[5] F. Hoffmann-La Roche Ltd,undefined
[6] Clinical Pharmacology and Quantitative Pharmacology,undefined
[7] AstraZeneca,undefined
[8] Gilead Sciences,undefined
[9] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 89卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：571 / 572
页数：1
相关论文
共 50 条
  • [1] Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Bei Wang
    Rong Deng
    Stefanie Hennig
    Tanja Badovinac Crnjevic
    Monika Kaewphluk
    Matts Kågedal
    Angelica L. Quartino
    Sandhya Girish
    Chunze Li
    Whitney P. Kirschbrown
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 499 - 512
  • [2] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (03) : 499 - 512
  • [3] Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study (vol 88, 499, 2021)
    Wang, Bei
    Deng, Rong
    Hennig, Stefanie
    Badovinac Crnjevic, Tanja
    Kaewphluk, Monika
    Kagedal, Matts
    Quartino, Angelica L.
    Girish, Sandhya
    Li, Chunze
    Kirschbrown, Whitney P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 571 - 572
  • [4] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
    DuMond, Barbara
    Patel, Vidhi
    Gross, Anne
    Fung, Anita
    Weber, Susan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1214 - 1221
  • [5] A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
    Ziegengeist, Julia L.
    Tan, Antoinette R.
    CLINICAL BREAST CANCER, 2025, 25 (02) : e124 - e132
  • [6] Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)
    Gregori, Joaquin Gavila
    Miranda, Elena Lopez
    Escriva-de-Romani, Santiago
    Rodriguez, Begona Jimenez
    Novoa, Silvia Antolin
    Morales, Luis Fernandez
    Calvo, Elena Galve
    Cortijo, Lucia Gonzalez
    Martorell, Antonia Perello
    Ruiz, Julian Lagunar
    Santiago, Santiago Gonzalez
    CANCER RESEARCH, 2022, 82 (04)
  • [7] Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
    Swain, Sandra M.
    Tan, Antoinette R.
    Gianni, Luca
    Kuemmel, Sherko
    Dang, Chau T.
    Schneeweiss, Andreas
    O'Shaughnessy, Joyce
    Liu, Haiying
    Aguila, Christian
    Heeson, Sarah
    Macharia, Harrison
    Yang, Ke
    Restuccia, Eleonora
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2023, 178 : 70 - 81
  • [8] FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS
    Bellone, M.
    Pradelli, L.
    Sanfilippo, A.
    Caputo, A.
    Manevy, M.
    Zerilli, A.
    VALUE IN HEALTH, 2022, 25 (01) : S109 - S109
  • [9] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
    Tan, Antoinette R.
    Im, Seock-Ah
    Mattar, Andre
    Colomer, Ramon
    Stroyakovskii, Daniil
    Nowecki, Zbigniew
    De laurentiis, Michelino
    Pierga, Jean-Yves
    Jung, Kyung Hae
    Schem, Christian
    Hogea, Alexandra
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Shivhare, Mahesh
    Kirschbrown, Whitney P.
    Restuccia, Eleonora
    Jackisch, Christian
    LANCET ONCOLOGY, 2021, 22 (01) : 85 - 97
  • [10] Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
    Whitney P. Kirschbrown
    Matts Kågedal
    Bei Wang
    Lars Lindbom
    Adam Knott
    Rachelle Mack
    Sharareh Monemi
    Ihsan Nijem
    Sandhya Girish
    Christie Freeman
    Debora Fumagalli
    Robin McConnell
    Guy Jerusalem
    Chris Twelves
    José Baselga
    Gunter von Minckwitz
    José Bines
    Amit Garg
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1147 - 1158
12345